Key Findings From Recent Trials

• INN (International Nonproprietary Name): Dydrogesterone
• Brand Names Available In United States: Not available; Duphaston was discontinued in the USA
• ATC Code: G03DB01
• Forms & Dosages: Tablet, 10 mg; blisters of 20 tablets
• Manufacturers In United States: Not specified (primary MAH is Laboratoires Abbott Products / Abbott/AbbVie; product not marketed in USA)
• Registration Status In United States: Not registered / discontinued in the USA
• OTC / Rx Classification: Prescription-only (Rx) in all markets where registered

Which recent studies matter if pregnancy is at risk after a positive test?

Randomized trials and systematic reviews published between 2022 and 2026 have trended toward favoring oral dydrogesterone for luteal support in assisted reproductive technology and for management of threatened and recurrent miscarriage.

Meta-analyses through 2024 report overall favorable signals for pregnancy maintenance when dydrogesterone is compared with placebo or no treatment, though the magnitude of benefit varies by study quality and by whether the study enrolled threatened versus recurrent miscarriage cohorts.

The strongest and most consistent reproductive outcomes favoring dydrogesterone are continued clinical pregnancy into the first trimester and reduced early pregnancy loss when therapy is started promptly after diagnosis.

Safety data from these trials show low rates of serious adverse events, with the most common complaints being mild nausea and breast tenderness.

Observational registries reporting birth outcomes do not show a consistent teratogenic signal, supporting an acceptable safety profile in early pregnancy.

In ART settings, trials also note dydrogesterone’s convenience as an oral progestogen compared with vaginal formulations, which affects adherence and patient preference.

These trial findings are relevant for clinicians deciding between oral dydrogesterone, micronized progesterone, or other progestins for luteal phase support or miscarriage prevention.

Keywords clinicians search for include threatened miscarriage treatment, luteal phase support evidence, and dydrogesterone trials when reviewing the literature.

Clinical Mechanism Of Action

What does dydrogesterone do in plain language?

Dydrogesterone is a synthetic progestogen that mimics natural progesterone’s effects on the uterus.

It stabilizes the endometrial lining, reduces uterine contractility, and supports implantation and early maintenance of pregnancy without producing strong androgenic or glucocorticoid effects.

How does it work at the receptor level?

Scientifically, dydrogesterone is a selective progesterone receptor agonist with high progestogenic potency and minimal activation of other steroid receptors.

This selectivity explains its favorable side-effect profile compared with older progestins that have androgenic or estrogenic activity.

What about pharmacokinetics?

Oral 10 mg tablets (marketed globally as Duphaston in blister packs) are systemically absorbed and undergo hepatic metabolism.

Product information cautions against use in severe liver disease because of hepatic handling.

No injectable or vaginal dydrogesterone formulations are marketed; the only advertised dosage form is the oral tablet.

What are the clinical consequences of this profile?

Dydrogesterone preserves ovulation at standard dosages, which is useful when progesterone replacement without ovulation suppression is desired in fertility treatment.

Its oral route makes it an attractive alternative to vaginal micronized progesterone for some patients concerned about local irritation or dosing inconvenience.

Scope Of Approved And Off-Label Use

Who is approved to use dydrogesterone, and what do clinicians use it for off-label?

Duphaston (dydrogesterone) has historically been marketed internationally but is discontinued in the United Kingdom and not available in the United States.

Where registered, it is prescription-only and labeled for conditions such as secondary amenorrhea and progesterone replacement indications.

Off-label and regionally approved uses are common and include luteal phase support in IVF and ICSI, treatment of threatened and habitual abortion, dysfunctional uterine bleeding, symptom control in endometriosis, and combined hormone replacement therapy regimens with estrogen.

Typical international regimens from product information list secondary amenorrhea at 10 mg twice daily and luteal insufficiency at 10 mg daily.

Threatened abortion protocols often report an initial loading phase followed by maintenance dosing, and habitual abortion regimens commonly continue 10 mg daily through at least week 20 of gestation per product guidance.

Duphaston remains registered in most European countries (excluding the UK), Russia, many Asian markets, and the Middle East.

Clinicians outside the USA frequently substitute or choose dydrogesterone because of its selectivity and oral convenience.

Patients should always receive informed consent when used off-label for fertility or miscarriage prevention.

Dosage Strategy

How is dydrogesterone dosed across conditions?

The standard marketed strength is a 10 mg oral tablet supplied in blisters of 20 tablets.

Adult dosing varies by indication and timing, and typical regimens use either once-daily or twice-daily schedules.

For secondary amenorrhea, the usual recommendation is 10 mg twice daily often given on cycle days 11–25.

Luteal phase support for infertility commonly uses 10 mg daily, often starting midluteal (around cycle day 14) and continuing to cycle day 25 or through early pregnancy for ART patients.

Dysfunctional uterine bleeding and dysmenorrhea protocols frequently prescribe 10 mg twice daily for short courses of 5–25 days depending on indication.

Threatened abortion regimens reported in practice begin with higher loading doses (for example, an initial 40 mg followed by 10 mg every 8 hours) and then transition to a maintenance dose.

Habitual abortion protocols typically continue 10 mg daily through at least the twentieth week of gestation per product labeling in many countries.

Adjustments are recommended for severe hepatic impairment—avoid use—and pediatric or elderly dosing is not well established and requires specialist guidance.

Safety Protocols

Who should not take dydrogesterone?

Absolute contraindications include known hypersensitivity to dydrogesterone or tablet excipients, progestogen-dependent tumors, active or severe liver disease, and undiagnosed vaginal bleeding.

Relative contraindications requiring close monitoring include a history of depression, thromboembolic disorders in the patient or family, uncontrolled hypertension, renal impairment, and diabetes mellitus.

What side effects are expected?

Common mild-to-moderate adverse events include breast tenderness, headache or migraine, nausea, abdominal discomfort, spotting or breakthrough bleeding, and rarely mild edema or fatigue.

Overdose carries a low-toxicity profile and is managed with symptomatic care; there is no specific antidote.

Regarding pregnancy safety, registries and clinical experience do not show a consistent teratogenic signal, and product information supports use in habitual abortion protocols through at least 20 weeks.

Clinicians should counsel patients about expected side effects and about prompt reporting of serious symptoms such as jaundice, severe abdominal pain, or signs of thrombosis.

Interaction Mapping

Will food or other drugs affect dydrogesterone?

Standard product information does not report major food interaction warnings; oral tablet absorption is generally reliable with or without food.

Storage advice includes keeping tablets below 30°C and protecting them from moisture and heat to preserve integrity.

Clinically important drug interactions center on hepatic metabolism.

Concomitant use with strong hepatic enzyme inducers such as certain anticonvulsants, rifampicin, or some antiretrovirals may lower dydrogesterone plasma levels and reduce clinical effect, so exercise caution and monitor response.

Because progestogens can influence thrombotic risk, combine dydrogesterone cautiously with agents that increase thrombosis risk and monitor high-risk patients closely.

When used as part of hormone replacement therapy alongside estrogen, follow established estrogen–progestogen scheduling; interactions with other steroid hormones are minimal due to dydrogesterone’s receptor selectivity.

Patient Experience Analysis

What do patients report when taking dydrogesterone?

Clinical surveys and registries report high patient tolerance overall, with most discontinuations driven by mild side effects like nausea, spotting, or breast discomfort.

In fertility cohorts, patients often describe perceived benefit when pregnancy progresses beyond the first trimester, and adherence is typically higher with oral dosing compared with vaginal progesterone options.

Patients in online forums from regions where Duphaston is available discuss the ease of oral dosing, concerns about availability in the UK and USA, and variability in pricing between pharmacies.

Common patient priorities include clear counseling on early pregnancy dosing schedules, expectations about side effects, and reassurance that dydrogesterone lacks androgenic activity.

Brand packaging mainly consists of 10 mg tablets in 20-count blisters, and supply stability varies by country and distributor.

Real-world feedback often favors dydrogesterone for convenience, but clinicians will substitute micronized progesterone or other progestins when Duphaston is unavailable.

Distribution And Pricing Landscape

Where is Duphaston sold and how is it priced?

Duphaston (Abbott/AbbVie MAH) is marketed globally outside the UK and USA, with strong distribution in Europe (excluding the UK), Russia/CIS, Asia, and parts of the Middle East.

The primary commercial format is 10 mg oral tablets in blister packs, with clinic-sized packs available for assisted reproduction cycles in some markets.

Laboratoires Abbott Products and local subsidiaries or licensed partners supply Duphaston in many jurisdictions, and significant generic penetration is not widely reported internationally.

Pricing varies regionally and is influenced by reimbursement policies, local manufacturing, and ART clinic demand.

Limited availability in the UK since 2008 and discontinued status in the USA drives clinicians and patients toward alternative progestins or micronized progesterone when Duphaston cannot be sourced.

Logistically, Duphaston requires regular solid oral-medication transport and storage below 30°C, with no cold chain necessary.

In our online pharmacy, duphaston is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

What are clinically appropriate alternatives if Duphaston is unavailable?

Key competitors include micronized progesterone (marketed as Prometrium), medroxyprogesterone acetate (Provera), and norethisterone or norethindrone acetate.

Micronized progesterone is bioidentical and available in vaginal formulations offering local endometrial effect and is commonly used in luteal support despite variable oral bioavailability and potential sedative effects in some oral formulations.

Medroxyprogesterone and norethisterone are widely available in multiple formulations including oral and injectable forms, but they may carry more androgenic or metabolic side effects depending on the molecule.

Dydrogesterone’s advantages are oral dosing convenience, selective progestogenic activity, and preservation of ovulation at standard doses.

Its disadvantages include lack of availability in some markets and absence of vaginal formulations for targeted local therapy.

Choice between agents depends on the indication—ART luteal support, bleeding disorders, or miscarriage prevention—the desired route of administration, safety profile, and regional availability.

Regulatory Status

What is the legal and regulatory picture for Duphaston?

Duphaston (dydrogesterone) is a prescription-only medicine in all markets where it is registered.

It is registered in most EU countries (excluding the UK), Russia, multiple Asian markets, and several Middle East jurisdictions, with Abbott/AbbVie listed as the primary marketing authorization holder in many regions.

Notable market withdrawals include discontinuation in the United Kingdom since 2008 and non-marketing in the United States.

National drug agencies and registries such as ANMDMR in Romania list Duphaston under dydrogesterone for prescription use, but local indications and labeling can vary by country.

Regulatory implications are that clinicians should consult their national product monograph for approved indications and dosing recommendations.

Off-label use is common in fertility care, but clinicians must obtain informed consent and adhere to local regulatory guidance when prescribing outside labeled indications.

Consolidated FAQ

Is Duphaston available in the USA or UK?

No; product information notes Duphaston was discontinued in the UK and is not available in the USA.

What is the common dose for luteal support?

Typical dosing for luteal support is 10 mg daily starting midluteal or according to ART protocol, though regimens may vary by clinic.

Can it be used in early pregnancy?

Yes; dydrogesterone is used in protocols for threatened and habitual abortion and is often continued through the first or into the second trimester per clinician judgment.

What are major contraindications?

Do not use if allergic to dydrogesterone, in progestogen-dependent tumors, active severe liver disease, or unexplained vaginal bleeding.

Does it inhibit ovulation?

No; available evidence shows no consistent ovulation inhibition at standard dosages, which is useful for preserving natural cycles during fertility treatment.

Visual Guide

How should clinicians and patients visualize packaging and dosing?

Commercial presentation is 10 mg oral tablets in blister packs of 20 tablets sold under the Duphaston brand in many countries.

Recommended clinical flow visuals include an indication decision tree that separates amenorrhea, luteal support, and threatened miscarriage pathways.

Dosing timeline graphics should show cycle-day windows for cyclical use versus continuous or maintenance dosing through early pregnancy in ART or miscarriage protocols.

Patient-facing visuals can include a pillbox layout for once-daily versus twice-daily dosing, a liver-function monitoring prompt, and a side-effect chart explaining when to call a clinician.

Storage iconography should emphasize storage below 30°C and keeping the drug in original blister packs to avoid moisture exposure.

Storage And Transport

How is Duphaston stored and shipped?

Product information advises storage below 30°C and protection from moisture and heat.

Transport as a standard solid oral medication is appropriate with no cold chain required.

Pharmacies and clinics typically dispense Duphaston in blister packs of 20 x 10 mg tablets, simplifying dosing checks for ART cycles.

Handle stock by retaining original packaging for correct dosing instructions and safety data, and avoid prolonged exposure to high temperatures during storage and transit.

International transport does not require special hazardous packaging, but regulatory import rules apply where the product is not registered, such as into the USA or UK.

Guidelines For Proper Use

What should prescribers and patients check before starting therapy?

Prescribing checklist: confirm the indication and consult national product monograph, review absolute contraindications such as allergy and severe liver disease, and counsel on expected side effects and missed-dose instructions.

Monitoring: consider baseline liver function testing if indicated, review psychiatric history for depression, assess thrombotic risk factors, and monitor glycemic control in patients with diabetes.

Recommended durations: infertility/ART often requires 3–6 cycles of therapy, endometriosis or amenorrhea treatment commonly 3–6 months, and threatened or habitual abortion protocols typically start promptly and may continue through the first or second trimester per clinician judgment.

Patient education should stress the prescription-only status of Duphaston in registered markets, storage below 30°C, and warning signs that warrant immediate medical attention, such as severe abdominal pain, jaundice, signs of thrombosis, or significant mood changes.

Delivery Across United States